Cargando…
Next-Generation Antisense Oligonucleotide of TGF-β2 Enhances T Cell-Mediated Anticancer Efficacy of Anti-PD-1 Therapy in a Humanized Mouse Model of Immune-Excluded Melanoma
SIMPLE SUMMARY: Upregulation of transforming growth factor-beta (TGF-β) signaling in melanoma contributes to the formation of immune-suppressive tumoral environments and is associated with poor response to immunotherapeutics, including anti-programmed death-1 (PD-1) therapy. Our study aimed to inves...
Autores principales: | Lee, Hong Kyu, Kim, Cho-Won, Ahn, Dohee, Go, Ryeo-Eun, Choi, Youngdong, Choi, Kyung-Chul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9654371/ https://www.ncbi.nlm.nih.gov/pubmed/36358638 http://dx.doi.org/10.3390/cancers14215220 |
Ejemplares similares
-
Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides
por: Anderson, Brooke A, et al.
Publicado: (2021) -
Targeting TGFβ Signaling to Address Fibrosis Using Antisense Oligonucleotides
por: March, James T., et al.
Publicado: (2018) -
Targeting TGF-β Signaling by Antisense Oligonucleotide-mediated Knockdown of TGF-β Type I Receptor
por: Kemaladewi, Dwi U, et al.
Publicado: (2014) -
Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy
por: van Deutekom, Judith, et al.
Publicado: (2023) -
Engineered adult stem cells: a promising tool for anti-cancer therapy
por: Choi, Youngdong, et al.
Publicado: (2023)